Drug Trial Radar · NCT03689374
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,274
Actual
Start
Oct 1, 2018
Primary completion
Feb 22, 2021
Study completion Feb 22, 2021
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get is decided by chance. Insulin glargine is taken once a day and semaglutide once a week. Insulin aspart is taken three times per day before a meal. All three medicines come in pre-filled pens for injection under the skin. The study will last for about 71 weeks. If participant's blood sugar gets under or over certain values participant will only participate in 14 weeks. The study doctor will inform the participant about this. The participant will have 15 clinic visits and 22 phone calls with the study doctor.
Conditions
- Diabetes Mellitus, Type 2
Interventions
SemaglutideDrug
Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.
Insulin aspartDrug
Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days
Insulin glargine U100Drug
Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycated Haemoglobin (HbA1c)Time frame: Baseline (week 0), week 52
Locations
210 sites in 21 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Banja Luka, Bosnia and Herzegovina
Novo Nordisk Investigational Site
Sarajevo, Bosnia and Herzegovina
Novo Nordisk Investigational Site
Tuzla, Bosnia and Herzegovina
Novo Nordisk Investigational Site
Burgas, Bulgaria
Novo Nordisk Investigational Site
Byala, Bulgaria
Novo Nordisk Investigational Site
Dimitrovgrad, Bulgaria
Novo Nordisk Investigational Site
Plovdiv, Bulgaria
Novo Nordisk Investigational Site
Rousse, Bulgaria
Novo Nordisk Investigational Site
Sofia, Bulgaria
Novo Nordisk Investigational Site
Stara Zagora, Bulgaria
Novo Nordisk Investigational Site
Stara Zagora, Bulgaria
Novo Nordisk Investigational Site
Varna, Bulgaria
Novo Nordisk Investigational Site
Karlovac, Croatia
Novo Nordisk Investigational Site
Osijek, Croatia
Novo Nordisk Investigational Site
Pula, Croatia
Novo Nordisk Investigational Site
Rijeka, Croatia
Novo Nordisk Investigational Site
Varaždin, Croatia
Novo Nordisk Investigational Site
Zagreb, Croatia
Novo Nordisk Investigational Site
Beroun, Czechia
Novo Nordisk Investigational Site
Brno, Czechia
Novo Nordisk Investigational Site
Kladno - Krocehlavy, Czechia
Novo Nordisk Investigational Site
Mladá Boleslav, Czechia
Novo Nordisk Investigational Site
Náchod, Czechia
Novo Nordisk Investigational Site
Olomouc, Czechia
Novo Nordisk Investigational Site
Pilsen, Czechia
Novo Nordisk Investigational Site
Prostějov, Czechia
Novo Nordisk Investigational Site
Pärnu, Estonia
Novo Nordisk Investigational Site
Tallinn, Estonia
Novo Nordisk Investigational Site
Tallinn, Estonia
Novo Nordisk Investigational Site
Tallinn, Estonia
Novo Nordisk Investigational Site
Viljandi, Estonia
Novo Nordisk Investigational Site
Bad Kreuznach, Germany
Novo Nordisk Investigational Site
Bad Mergentheim, Germany
Novo Nordisk Investigational Site
Berlin, Germany
Novo Nordisk Investigational Site
Berlin, Germany
Novo Nordisk Investigational Site
Berlin, Germany
Novo Nordisk Investigational Site
Berlin, Germany
Novo Nordisk Investigational Site
Eisenach, Germany
Novo Nordisk Investigational Site
Essen, Germany
Novo Nordisk Investigational Site
Essen, Germany
Showing 40 of 210 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.